Announcements
- Lantheus Acquires Global Rights to Life Molecular Imaging’s Novel Therapeutic and Diagnostic Pair Targeting GRPR for Prostate and Breast Cancers
- Lantheus’ AI-Enabled aPROMISE Now Available on Siemens Healthineers’ syngo.via platform
- Lantheus to Present at the William Blair 44th Annual Growth Stock Conference
- Lantheus Announces Executive Appointments to Accelerate Innovation
- Lantheus Reports First Quarter 2024 Financial Results
- Lantheus to Host First Quarter 2024 Earnings Conference Call and Webcast on May 2, 2024, at 8:00 a.m. Eastern Time
- Lantheus to Present at the Leerink Partners Global Biopharma Conference 2024
- Lantheus Announces the FDA Approval of DEFINITY® (Perflutren Lipid Microsphere) for Pediatric Patients
- Lantheus Announces Promotion of Amanda Morgan to Chief Commercial Officer
- Lantheus to Present at the TD Cowen 44th Annual Health Care Conference
More ▼
Key statistics
As of last trade Lantheus Holdings Inc (0L8:BER) traded at 72.54, -10.18% below its 52-week high of 80.76, set on Jul 19, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 72.54 |
---|---|
High | 72.54 |
Low | 72.54 |
Bid | 72.60 |
Offer | 73.60 |
Previous close | 73.92 |
Average volume | 192.56 |
---|---|
Shares outstanding | 69.31m |
Free float | 67.53m |
P/E (TTM) | 12.21 |
Market cap | 5.55bn USD |
EPS (TTM) | 6.55 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 07:03 BST.
More ▼